From: Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs
Antigen | Vaccine type | Adjuvant | Route | Nb of vaccinations | Humoral response | CMI responsea | Other/comments | References | |
---|---|---|---|---|---|---|---|---|---|
Serum | BALFb | ||||||||
P71 | Subunit | Mycobacterium tuberculosis ESAT-6 recombinant protein | IM | 2 | IgG1, IgG2a IgG2a/IgG1 ≈1 (with) < 1 (without adjuvant) |  | IFN-γ, low Il-10 |  | [82] |
P97 (R1) | Subunit and its chimeric from with LTBb |  | IM or IN | 3 | IgG, IgG1, IgG2a (only with chimeric form) IM: IgG2a/IgG1 = 1.2 IN: IgG2a/IgG1 = 0.6 | IgA (only with chimeric form) | IFN-γ response (only with chimeric form and IN application) | No anti-R1 antibodies with commercial bacterin | [83] |
P97 (R1,R1R2) | Subunit and their chimeric forms with LTB | Montanide IMS 1113 | IM | 3 | IgG | IgA, IgG | IFN-γ | Highest humoral response with chimeric forms | [84] |
HSP70 | Subunit | Nanoparticles SBa-15 and SBa-16, Aluminium | IP | 3 | IgG |  | Only in SBa-15 group; IFN-γ, Il-4, Il-10 | Effect SBa-15 comparable to Aluminium | [85] |
P97R1, P46, P95, P42 | Chimeric – recombinant E. coli bacterin | Oil adjuvant (AddaVax™) (for chimeric) | IM | 2 | IgG, IgG1, IgG2a (IgG2a /IgG1≈0.8) |  |  | Antibodies against each antigen; higher response in chimeric group | [86] |